New Releases from NCBI BookshelfMirikizumab for treating moderately to severely active ulcerative colitis.Mirikizumab for treating moderately to severely active ulcerative colitis.
Post Content
Uncategorized
Uncategorized
New Releases from NCBI BookshelfDecitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal).Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal).
Post Content
Uncategorized
New Releases from NCBI BookshelfAxicabtagene ciloleucel (DLBCL and HGBL, second line): Benefit assessment according to §35a SGB V, (expiry of the decision): IQWiG Reports – Commission No. A24-71 [Internet].Axicabtagene ciloleucel (DLBCL and HGBL, second line): Benefit assessment according to §35a SGB V, (expiry of the decision): IQWiG Reports – Commission No. A24-71 [Internet].
Post Content
Uncategorized
New Releases from NCBI BookshelfDurvalumab (endometrial cancer, pMMR): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A24-86 [Internet].Durvalumab (endometrial cancer, pMMR): Benefit assessment according to §35a SGB V, : IQWiG Reports – Commission No. A24-86 [Internet].
Post Content
Uncategorized
New Releases from NCBI BookshelfLutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments.Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments.
Post Content
Uncategorized
New Releases from NCBI BookshelfCabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine.Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine.
Post Content